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Abstract 
Background: In patients with adrenal incidentalomas (AI), there is uncertainty on how to rule out 
hypercortisolism. The occurrence of post-surgical (unilateral adrenalectomy) hypocortisolism (PSH) 
has been proposed as a proof of the presence of a pre-surgical hypercortisolism in AI patients. The 
aim of this study was to define the thresholds of cortisol level after 1 mg overnight dexamethasone 
suppression test (F-1mgDST), urinary free cortisol (UFC), midnight serum cortisol (MSC) and 
adrenocorticotroph hormone (ACTH) able to predict the absence of PSH in AI patients undergoing 
surgery. 
Methods: In 60 patients who underwent AI excision, cortisol secretion was assessed by low-dose 
corticotropin stimulation test or insulin tolerance test, when needed. We searched for the lowest pre-
surgical value of F-1mgDST, UFC and MSC and the highest value for ACTH in AI patients with PSH 
as indexes of normal cortisol secretion. 
Results: the lowest values of F-1mgDST, UFC and MSC and the highest value for ACTH in PSH 
patients were 1.2 µg/dL (33 nmol/L), 10.4 µg/24h (29 nmol/24h), 1.2 µg/dL (33 nmol/L) and 26.9 
pg/ml (6 pmol/L), respectively, but only F-1mgDST <1.2 µg/dL (33 nmol/L) was able to predict the 
absence of PSH. Among AI patients with F-1mgDST <1.2 µg/dL (33 nmol/L) no subjects had 
diabetes mellitus and/or metabolic syndrome and these subjects tended to have a better metabolic 
profile than those with F-1mgDST ≥1.2 µg/dL (33nmol/L) 
Conclusion: in AI patients a F-1mgDST <1.2 μg/dL (33 nmol/L) rules out PSH and could be used to 
exclude hypercortisolism in AI patients. 
Précis: In patients with adrenal incidentalomas the cortisol after 1 mg overnight dexamethasone 
suppression test <1.2 μg/dL (33 nmol/L) excludes hypercortisolism. 
Key words: cortisol, 1-mg overnight  dexamethasone suppression test, adrenal incidentalomas, 
hypocortisolism 
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Introduction 
In the recent years several studies showed that in patients with incidentally discovered adrenal 
masses (AI) but without the classical signs and symptoms of cortisol excess, the presence of a less 
severe hypercortisolism (previously called autonomous cortisol excess, possible autonomous cortisol 
excess or subclinical hypercortisolism) was associated with an increased mortality, mainly due to an 
elevated risk of cardiovascular events (1-5). In fact, these findings were somewhat expected, since in 
the last decades many studies showed an increased frequency of cardiovascular risk factors (5) and 
their reduction after adrenalectomy (6) in AI patients with less severe hypercortisolism. 
Nevetheless, several works reported an increased risk of cardiovascular disease (7-11) or 
diabetes mellitus (12) even in patients with non-functioning AI (NFAI). In keeping, recently, the 
mortality associated with the presence of NFAI has been found to be similar to that in AI patients with 
a less severe hypercortisolism (13), and a metanalysis showed that adrenalectomy could reduce the 
risk of hypertension and diabetes mellitus even in patients with NFAI (6).  
The unexpected finding of the increased cardiovascular risk even in NFAI patients was 
suggested to be due to an exaggerated cortisol response to stress (11), an increased secretion of steroid 
precursors (14-16), a cyclic cortisol secretion (17) and to variations in the individual cortisol 
sensitivity (18). Alternatively, it has been proposed that these tumours have a subtle cortisol 
(hyper)secretion (19, 20), that cannot be disclosed by the currently used parameters of hypothalamic-
pituitary-adrenal (HPA) axis activity. If this was the case, the current cut-offs used for the definition 
of hypercortisolism in AI patients may be inadequate. This idea is in keeping with the fact that 
cortisol after dexamethasone suppression test with a cut-off set at 1.4-1.5 μg/dL (39-41 nmol/L), 
rather than at 1.8 μg/dL (50 nmol/L, as currently used) had the highest accuracy in predicting 
cardiovascular risk (11, 21) or the incidence of diabetes mellitus (12) in AI patients.  
By definition, AI patients are asymptomatic for the classic signs and symptoms of 
hypercortisolism. However, the occurrence of post-surgical hypocortisolism (PSH) has been proposed 
as an indirect proof of the presence of an autonomous cortisol secretion by these tumours (5, 22, 23).  
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Therefore, the aim of the present study was to define the absence of hypercortisolism in AI by 
assessing the cut-offs of F-1mgDST and other parameters of HPA axis activity able to predict the 
absence of PSH in AI patients undergoing surgery.  
Patients and Methods 
Patients 
The current study is based on the population of a previous study aimed to evaluate whether, in 
AI patients undergoing unilateral adrenalectomy, PSH could be predicted by the parameters of HPA 
axis function (22). In that study, performed from December 2003 to December 2008, 319 consecutive 
AI patients with unilateral AI and without signs and/or symptoms specific of cortisol excess (moon 
facies, striae rubrae, skin atrophy, buffalo hump) have been enrolled. In all patients, a unilateral 
adrenal mass was incidentally found by non-invasive imaging methods of the abdomen performed for 
other causes. No subject had evidence of metastatic diseases.  At computed tomography all adrenal 
masses were consistent with the diagnosis of adrenocortical adenomas (i.e: homogeneous, hypodense 
below 10 Hounsfield units and with well-shaped features). We excluded 61 patients taking drugs or 
affected with diseases influencing cortisol metabolism and/or secretion (i.e. rheumatologic or 
haematological diseases, depression, alcoholism, eating disorders, bowel diseases, thyrotoxicosis and 
chronic renal and/or hepatic disease) and 18 patients with pheochromocytoma (n=8) or aldosterone-
secreting adenoma (n=10). Among the remaining 240 AI patients, 60 underwent surgical removal of 
the adrenal mass due to the presence of hypercortisolism and/or on the basis of the size of the lesion 
and were included in the study. Figure 1 summarizes the protocol used. 
In all patients, at baseline, the following parameters have been measured at least once: basal 
morning (08.00 h) adrenocorticotroph hormone (ACTH), urinary free cortisol (UFC), midnight serum 
cortisol (MSC) and F-1mgDST levels. For each subject, the mean values of these parameters were 
reported, if more than one determination was available during the pre-surgical follow-up, which lasted 
from 15 days to 24 months. 
In 31 patients, surgery was considered the best therapeutic option on the basis of the 
increasing dimensions (>1 cm increase during 12 months of follow up) or a size larger than 4 cm at 
the diagnosis. None of these patients had a clearly fluctuating cortisol secretion. In 29 patients, even 
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though completely asymptomatic for hypercortisolism, the surgical operation was decided on the basis 
of biochemical data strongly suggesting the presence of cortisol excess, such as the presence of ≥3 
criteria out the following : 1) UFC levels >60 g/24h (165 nmol/24h, the 97th percentile of a 
reference population for UFC), 2) F-1mgDST >3.0 g/dL (83 nmol/L), 3) ACTH levels <10 pg/mL 
(2.2 pmol/L), iv) MSC >5.4 g/dL (149 nmol/L), as suggested by other authors (24). 
Laparoscopic or laparotomic adrenalectomy was decided by the endocrine surgeon, depending on the 
size of the adrenal adenoma and the patients’ clinical characteristics. In all cases histology were 
consistent with adrenocortical adenoma. No patient had peri-operative and post-operative 
complications.  
Since adrenal failure occurs is more frequent during stressful events, and following the 
recommendations of the Italian Association of Clinical Endocrinologists (24), we administered in all 
patients a precautionary steroid therapy during surgery with hydrocortisone [100 mg i.v., on the basis 
of the   
anesthesiological protocol used in our Hospital, at the time of the study] and immediately after 
operation with cortisone acetate per os (at weight-related dosing ranging between 25 and 37.5 mg/day 
in 3 subdivided doses during the day corresponding to 20-30 mg/day hydrocortisone), in order to 
avoid the possible consequences of an undiagnosed hypoadrenalism (24). The starting cortisone 
acetate dose was weight-adjusted (corresponding to 0.3 mg/kg per day hydrocortisone).  The 
commonly used cortisone acetate dose was 25 mg/day (corresponding to hydrocortisone 20 mg/day, 
51 patients), while higher doses of 31.3 and 37.5 mg/day (corresponding to 25 and 30 mg/day 
hydrocortisone) were used in 7 and 2 patients, respectively.  
In all patients, after about 60 days, the cortisol secretion was assessed by low dose 
corticotropin stimulation test (LDCT), after a 24-hours steroid therapy withdrawal (25). The timing of 
the assessment of HPA axis function had been decided to avoid the persistence of a post-operative 
stress condition, as in this setting LDCT has not been validated (26, 27). At the time of the study we 
used the cut-offs of 16 μg/dl (440 nmol/L) and 22 μg/dL (600 nmol/L) for diagnosing PSH and for 
ruling out PSH, respectively on the basis of data showing that LDCT stimulated cortisol values less 
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than 16 μg/dL (440 nmol/L) best predicted adrenal insufficiency, whereas values greater than 22 
μg/dL (600 nmol/L) best predicted a normal adrenal function with a good accuracy (area under the 
curve 0.94, 95% confidence interval  0.90 – 0.94) (26) 
In 21 patients with baseline cortisol >5 g/dL (138 nmol/L) and stimulated cortisol levels >22 
g/dL (600 nmol/L), PSH was ruled out and the steroid substitutive therapy was withdrawn, with 
none of these patients having symptoms suggesting PSH. At variance, 34 patients with baseline 
cortisol <5 g/dL (138 nmol/L) and/or stimulated cortisol levels <16 g/dL (441 nmol/L) were 
considered affected with PSH. Five patients with baseline cortisol >5 g/dL (138 nmol/L) and LDCT 
stimulated cortisol levels between 16 μg/dL (441 nmol/L) and 22 g/dL (600 nmol/L) underwent 
insulin tolerance test (ITT) (27, 28). The latter subjects showed a reduced cortisol response after ITT 
[i.e stimulated cortisol levels <18 g/dL (496 nmol/L), at any time during the test in the presence of 
symptomatic hypoglycaemia and plasma glucose <40 mg/dL (2.22 mmol/L)] (27, 28) and were, 
therefore, diagnosed as having PSH.  
We decided to use an higher cut-off  (i.e. 22 μg/dL, 600 nmol/L, rather than 18 μg/dL, 500 
nmol/L) in order to improve sensitivity. Indeed, an higher cut-off may be needed in patients after 
withdrawal of inhalatory steroid therapy, who might be comparable to those with a previous 
endogenous mild hypercortisolism (29). 
Overall, 39 patients were found to have PSH and were re-tested by LDCT every 6 months. 
The PSH lasted 6, 12, 18, 24 and 36 months in 6, 15, 9, 7 and 2 patients, respectively.  
All subjects gave their witnessed informed consent before entering the study, which was approved by 
local ethical Committees and in accordance with Helsinki Declaration II. 
Methods 
All samples were stored at –20°C until assayed. The assays used were the same in all 
centers. In all patients plasma ACTH levels (mean of 3 determinations at 20-minute intervals) were 
measured by IRMA (BRAHMS Diagnostica GmbH, Berlin, Germany) and serum cortisol and UFC 
levels (after dichloromethane extraction) were determined immunofluorimetrically by TDX-FLX 
Abbott, GmbH, Diagnostika kits (Wiesbaden-Delkenheim, Germany). The intra- and inter-assay 
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coefficients of variation for all assays were <5 and 10%, respectively. Low dose corticotropin 
stimulation and ITT tests were performed as described elsewhere (22)  
We recorded the following data: weight, height, body mass index (BMI), presence of arterial 
hypertension, obesity, dyslipidaemia, diabetes mellitus and metabolic syndrome following the World 
Health Organization criteria published in 2001 (30), as at the time of the data collection those were 
the commonly used criteria for diagnosing diabetes mellitus. However, the criteria to diagnose 
diabetes have changed during the last 10 years. Therefore, in this analysis, we reassessed these 
diagnoses on the basis of the new criteria (31) and we did not find differences in the diagnostic 
classification. 
Study Design and Statistical Analysis 
We postulated that the presence of PSH is an indirect sign of a presurgical hypercortisolism. 
We firstly compared patients with and without PSH. Then, we searched for the lowest value of F-
1mgDST, UFC and MSC and for the highest value for ACTH in patients with PSH. Since, by 
definition, in our cohort no patients with PSH, and therefore with presurgical hypercortisolism, had F-
1mgDST, UFC and MSC below and ACTH above those values, we considered these cut-offs as those 
that possibly individuate AI patients without hypercortisolism. Then, we assessed the sensitivity (SN), 
specificity (SP), positive and negative predictive values (PPV and NPV, respectively) of these 
parameters for identifying the absence of PSH occurrence and considered them as possible indexes of 
the absence of hypercortisolism. Furthermore, we compared the clinical characteristics of patients 
grouped on the basis of the HPA axis parameters and their cut-off that resulted to be able to 
significantly rule out the PSH occurrence.  
Statistical analysis was performed by SPSS version 26.0 statistical package (IBM SPSS, 
Milan, Italy). The results are expressed as mean ± SD, if not differently specified. The normality of 
data distribution was tested by Kolmogorov–Smirnov test.  
The comparison of the continuous variables were performed using the Student’s t-test or 
Mann–Whitney U-test as appropriate, while the categorical were compared by χ2 test or Fisher Exact 
test, as appropriate. The bivariate associations were tested by Spearman rho or Pearson correlation as 
appropriate. 
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 P-values of less than 0.05 were considered significant. 
 
 
 
 
 
 
 
Results 
The clinical characteristics of patients with or without PSH occurrence are summarized in 
Table 1. The two groups were comparable for age, BMI, diameter of adenoma, duration of pre-
surgical follow-up, mean hydrocortisone equivalent daily dose, indication for which surgery was 
chosen (i.e. size of adenoma or suspected subclinical hypercortisolism) and prevalence of 
hypertension, type 2 diabetes, obesity and metabolic syndrome. Among the HPA axis function’s 
parameters, MSC levels were significantly higher in patients with PSH than in those without, whereas 
UFC, 1mg-DST and ACTH levels were comparable between the two groups. The lowest value of F-
1mgDST, UFC and MSC and the highest value for ACTH in patients with PSH were 1.2 µg/dL (33 
nmol/L), 10.4 µg/24h (29 nmol/24h), 1.2 µg/dL (33 nmol/L) and 26.9 pg/ml (6 pmol/L), respectively. 
The prevalence of post-surgical hypocortisolism was not different between patients selected for 
surgery by size criteria (18/31 58%) or because of hypercortisolism (21/29, 72.4%, P=0.287). 
The number of subjects with F-1mgDST <1.2 µg/dL (33 nmol/L), UFC <10.4 µg/24h (29 
nmol/24h), MSC <1.2 µg/dL (33 nmol/L) and ACTH >26.9 pg/mL (6 pmol/L) among patients with 
PSH and without PSH are also reported in Table 1. Among patients without PSH, 9, 2, 1 and 1 
individuals showed F-1mgDST F-1mgDST <1.2 µg/dL (33 nmol/L), UFC <10.4 µg/24h (29 
nmol/24h), MSC <1.2 µg/dL (33 nmol/L) and ACTH >26.9 pg/mL (6 pmol/L), respectively (Figure 
2). As noted, the statistical significance was obtained only for F-1mgDST, probably due to the low 
number of patients with MSC levels below 1.2 µg/dL (33 nmol/L), UFC levels below 10.4 µg/24h (29 
nmol/24h) and ACTH values above 26.9 pg/mL (6 pmol/L). Therefore, in this cohort we considered 
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F-1mgDST test as the only one with enough reliability to be investigated as possible marker of the 
absence of PSH occurrence after surgery.  
By using a F-1mgDST cut-off set at 1.2 µg/dL (33 nmol/L, the lowest value in patients with 
PSH occurrence), we obtained a 100% SN and PPV (as expected) and a 42.9% SP and 76.5% NPV 
(accuracy 66.6%, p<0.0001). The comparison between patients grouped on the basis of a F-1mgDST 
cut-off  ≥1.2 µg/dL or <1.2 µg/dL (33 nmol/L)  is reported in table 2. Age, BMI, duration of pre-
surgical follow-up, mean hydrocortisone equivalent daily doses, ACTH levels and diameter of the 
adenoma were comparable between the two groups, while F-1mgDST (by definition), UFC and MSC 
levels were higher in patients with F-1mgDST ≥1.2 µg/dL (33 nmol/L) than in those with F-1mgDST 
<1.2 µg/dL (33 nmol/L).  This latter group showed a lower prevalence of dyslipidemia and tended to 
have a lower prevalence of diabetes mellitus than the former. Interestingly, among the 9 patients with 
F-1mgDST <1.2 µg/dL (33 nmol/L), no subjects were affected with diabetes mellitus and/or 
dyslipidemia and/or metabolic syndrome.                                     
Discussion 
 In AI patients, who underwent unilateral adrenalectomy, the PSH occurrence has been 
suggested to be an indirect proof of the presence of hypercortisolism before surgery (5, 22, 23). 
Therefore, the aim of the present study was to define how to exclude hypercortisolism in AI on the 
basis of the cut-off of F-1mgDST, MSC, UFC and ACTH able to predict in AI patients before surgery 
the absence of hypocortisolism after surgery. In our cohort, only F-1mgDST levels measured before 
surgery with a cut-off set at 1.2 μg/dL (33 nmol/L) could predict the PSH absence. Indeed, no AI 
patients with F-1mgDST below 1.2 μg/dL  (33 nmol/L) experienced the PSH occurrence. Moreover, 
AI patients with F-1mgDST <1.2 μg/dL (33 nmol/L) tended to show a better metabolic profile as 
compared with those with F-1mgDST ≥1.2 μg/dL (33 nmol/L). These findings could suggest that in 
AI patients the F-1mgDST cut-off for defining the absence of hypercortisolism should be lowered to 
1.2 μg/dL (33 nmol/L). 
The present findings are in line with some previous data. Indeed, in AI patients cortisol after 2 
days low dose (i.e. 2 mg/day) dexamethasone suppression test with a cut-off set at 1.4 μg/dL (39 
nmol/L) and 1.1 μg/dL (30 nmol/L) had the higher accuracy in predicting cardiovascular risk and 
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insulin-resistance, respectively (11) and the F-1mgDST cut-off with the best conciliation between SN 
and SP for predicting cardiovascular events was found to be as low as 1.5 μg/dL (41 nmol/L) (21). 
Moreover, previous studies showed that in patients with NFAI (F-1mgDST <1.8 μg/dL, 50 nmol/L) 
the incidence of diabetes mellitus was increased as compared with patients without AI (12) and the 
removal of an NFAI can lead to an amelioration of blood pressure, diabetes mellitus and dyslipidemia 
(6, 21). Finally, a recent meta-analysis showed that the mortality was not differently increased in AI 
patients with autonomous cortisol secretion as compared with NFAI patients (13).  
The finding in the present cohort of AI patients with F-1mgDST <1.2 μg/dL (33 nmol/L) 
being less frequently affected with dyslipidaemia and having a better metabolic profile is in 
agreement with the idea that at least some of the currently so called “non-functioning” adrenal 
adenomas, are, in fact, responsible of a subtle but significant degree of cortisol hypersecretion. The 
hypothesis that some AI patients, who are not considered as affected with hypercortisolism on the 
basis of the F-1mgDST level <1.8 μg/dL (50 nmol/L), may instead be hypercortisolemic, had already 
been proposed by other Authors in the past (19), but no suggestion on lowering the cut-off for F-
1mgDST was given. Importantly, a lower cut-off of F-1mgDST has recently been proposed on the 
basis of data coming from subjects without AI and eucortisolemic (i.e. with F-1mgDST <1.8 μg/dL, 
50 nmol/L). Indeed, we have recently reported that in postmenopausal women without 
hypercortisolism, an abnormal cortisol secretion is associated with hypertension (32) and the cut-off 
of F-1mgDST set at 0.9 μg/dL (25 nmol/L) may be used for predicting the presence of at least 2 
among hypertension, diabetes mellitus and fragility fractures (33). In keeping, the role of cortisol 
secretion, even within the “normal” range, has been recently suggested as index of cardiovascular risk 
by three independent research groups (34-36).  
It must be observed that the F-1mgDST cut-off set at 1.2 μg/dL (33 nmol/L), while possibly 
useful for ruling out PSH and, therefore, for predicting the absence of hypercortisolism in AI, cannot 
be used for predicting the certain PSH occurrence. Even in our cohort, many patients with F-1mgDST 
≥1.2 μg/dL (33 nmol/L) did not develop PSH (22), as already reported even in patients with clinically 
overt ACTH-independent hypercortisolism (37). The different duration of the cortisol hypersecretion, 
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the different sensitivity to glucocorticoids and the different peripheral activation of cortisol may be all 
possible explanations of this apparently contradictory finding.  
This study has several limits. Firstly, the low number of patients, in particular among those 
who did not experience PSH, suggests that the present findings should be taken with extreme caution. 
Secondly, we cannot completely exclude that some patients were affected with a cyclic form of 
hypercortisolism, thus rendering the F-1mgDST values less reliable. Thirdly, we should consider the 
possibility that in patients with F-1mgDST <1.2 μg/dL (33 nmol/L) the lack of PSH could be due to a 
short disease duration, that could not have been sufficient to induce the HPA axis impairment, rather 
than being an index of a normal cortisol secretion. However, the fact that the pre-surgical follow-up 
duration was not shorter in AI patients with F-mgDST <1.2 μg/dL (33 nmol/L) than in those with F-
1mgDST ≥1.2 μg/dL (33 nmol/L) is against this possibility. We are aware that, nowadays, the 
recommended hydrocortisone-equivalent doses for the glucocorticoid substitutive therapy are slightly 
lower (i.e. hydrocortisone 15–20 mg/day or cortisone acetate 20–25 mg/day) than those used at the 
time of the study (38). This is due to the fact that immediately after the resolution of an adrenal 
hypercortisolism a substitutive dose of hydrocortisone of 12–15 mg/m2/day has been recommended 
because it was enough to prevent adrenal crisis and to allow a recovery of the HPA axis (39, 40). 
Moreover, our protocol did not allow a step-by-step decrease in the dose of glucocorticoid 
substitution. Therefore, we cannot exclude that the high and not modifiable doses of glucocorticoid 
substitutive therapy might have influenced the present rate of post-operative hypocortisolism (i.e. 
70.9%), which, however, was in keeping with that (i.e. 50-90%) reported in the literature (39). We 
cannot exclude also that the long PSH duration in some patients could have been influenced by the 
relatively high and not-modifiable dose of glucocorticoid substitutive therapy. However, the PSH 
duration in patients operated on for adrenal adenomas is reported to vary between 1 months and 50 
months (39), figures that are in keeping with the present findings. In addition, we did not measure 
dexamethasone levels in blood, and, therefore, we cannot be sure that the HPA axis activity 
suppression was adequate in all patients. Finally, these results are derived from a cohort of patients 
operated on for adrenal adenomas and, therefore, the generalizability of these findings is limited  
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However, notwithstanding these limits, the present study suggests for the first time that the F-
1mgDST cut-off below 1.2 μg/dL (33 nmol/L) is able to rule out the possible occurrence of 
hypocortisolism in AI patients undergoing the removal of the adrenal adenoma. A first consequence 
of the present findings is that in AI patients with  F-1mgDST below 1.2 μg/dL before surgery, a post-
operative glucocorticoid substitutive therapy is not needed. In addition, this F-1mgDST cut-off has the 
highest sensitivity to exclude hypercortisolism and, at least in AI patients, could define a normal 
cortisol secretion. Further studies with a thorough and prolonged endocrine workup before surgery in 
AI patients, are needed to confirm the need of lowering the currently used F-1mgDST cut-off for 
defining normal cortisol secretion. 
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Figure 1 Legend 
Flow chart reporting the inclusion criteria, reasons for  adrenalectomy, assessments and protocol. 
Footnotes: 319 consecutive patients with unilateral incidentally found adrenal adenoma (adrenal 
incidentaloma) and without signs and/or symptoms specific of cortisol excess (moon facies, striae 
rubrae, skin atrophy, buffalo hump) have been enrolled. We excluded 61 patients taking drugs or 
affected with diseases influencing cortisol metabolism and/or secretion (i.e. rheumatologic or 
haematological diseases, depression, alcoholism, eating disorders, bowel diseases, thyrotoxicosis and 
chronic renal and/or hepatic disease) and 18 patients with pheochromocytoma (n=8) or aldosterone-
secreting adenoma (n=10). Among the remaining 240 patients, 60 underwent surgical removal of the 
adrenal mass on the basis of the size of the lesion or due to the presence of hypercortisolism [i.e. 
presence of ≥3 criteria out the following : 1) Urinary free cortisol levels >60 g/24h (165 nmol/24h, 
the 97th percentile of a reference population), 2) cortisol after 1 mg-overnight dexamethasone 
suppression test >3.0 g/dL (83 nmol/L), 3) adrenocorticotroph hormone levels <10 pg/mL (2.2 
pmol/L), iv) midnight serum cortisol levels >5.4 g/dL (149 nmol/L)].  
In all patients, after about 60 days, the cortisol secretion was assessed by low dose 
corticotropin stimulation test (LDCT), In 21 patients with baseline cortisol >5 g/dL (138 nmol/L) 
and stimulated cortisol levels >22 g/dL (600 nmol/L), post-surgical hypocortisolism (PSH) was 
ruled out and the steroid substitutive therapy was withdrawn (PSH absent). At variance, 34 patients 
with baseline cortisol <5 g/dL (138 nmol/L) and/or stimulated cortisol levels <16 g/dL (441 
nmol/L) were considered affected with PSH (PSH present). Five patients with possible PSH [i.e. 
baseline cortisol >5 g/dL (138 nmol/L) and LDCT stimulated cortisol levels between 16 g/dL (441 
nmol/L) and 22 g/dL (600 nmol/L)] underwent insulin tolerance test (ITT). All these latter subjects 
showed a reduced cortisol response after ITT [i.e stimulated cortisol levels <18 g/dL (496 nmol/L)] 
and were, therefore, diagnosed as having PSH.  
Overall, 39 patients were found to have PSH and were re-tested by LDCT every 6 months. 
The PSH lasted 6, 12, 18, 24 and 36 months in 6, 15, 9, 7 and 2 patients, respectively. 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/jes/advance-article-abstract/doi/10.1210/jendso/bvaa079/5860152 by guest on 20 June 2020
Ac
ce
pte
d M
an
us
cri
pt
 
20 
 
 
 
Figure 2 Legend 
Presurgical levels of cortisol after 1 mg overnight dexamethasone suppression test (F-1mgDST) and 
midnight serum cortisol (MSC) in 60 patients with adrenal incidentalomas (AI) who underwent 
adrenalectomy. 
Footnotes: all AI patients with a post-surgical hypeocortisolism (PSH) occurrence (black diamonds) 
showed F-1mgDST ≥1.2 μg/dL (33 nmol/L, vertical line) or MSC ≥1.2 μg/dL (33 nmol/L, horizontal 
line). In our cohort, 9 and 1 patients without PSH (empty circles) showed F-1mgDST or MSC <1.2 
μg/dL (33 nmol/L). 
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Table 1. Pre-surgical clinical and biochemical features of patients with adrenal incidentalomas and 
without (PSH-) or with post-surgical hypocortisolism (PSH+) 
 
Group PSH+ 
n = 39 
Group PSH- 
n = 21 
P value 
Females 31 15 0.532 
Age                                            
(yrs)  
55.3 ± 12.0   
(24 - 74) 
57.2 ± 8.3  
(33 - 75) 
0.505 
BMI                                      
(kg/m
2
) 
27.4 ± 5.6  
(17.4 – 41) 
29.6 ± 5.4  
(21.5 – 41) 
0.163 
Reason for surgery          
(size of the mass/SH) 
18/21 13/8 0.287 
HC doses (mg/day) 
20.9±2.6 
(20 – 30) 
20.9±2.3 
(20 – 30) 
0.932 
ACTH  
(pg/mL) 
9.6 ± 5.7 
(1.9 – 26.9) 
9.0 ± 4.4 
(5.0 – 23.8) 
0.665 
ACTH >26.9 pg/mL 
(%) 
0 
(0.0) 
1 
(1.7) 
0.650 
F-1mg-DST 
 (µg/dL) 
4.6 ± 3.5 
(1.2 – 13.7) 
3.2 ± 2.1 
(0.9 – 9.0) 
0.098 
F-1mg-DST <1.2 µg/dL 
(%) 
0 
(0.0) 
9 
(42.9) 
<0.0001 
UFC  
(µg/24hrs) 
68.2 ± 45.2 
(10.4 – 189.6) 
51.3 ± 32.4 
(10.0 - 120.0) 
0.136 
UFC <10.4 µg/24hrs 
0 
(0.0) 
2 
(9.5) 
0.119 
MSC 
(µg/dL) 
6.0 ±3.1  
(1.2 – 12.5) 
3.4 ± 2.0 
(1.0 – 8.0) 
0.001 
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MSC <1.2 µg/dL 
0 
(0.0) 
1 
(4.8) 
0.350 
Diameter of adenoma 
(cm) 
3.5 ± 1.3 
(1.2 – 9.0) 
3.2 ± 1.0 
(1.5 – 5.7) 
0.340 
Pts with type 2 diabetes mellitus 
(%) 
9 
(23.1) 
5 
(23.8) 
1.000 
Pts with arterial hypertension 
(%) 
18 
(46.2) 
15 
(71.4) 
0.102 
Pts with obesity 
(%) 
15  
(38.5) 
10 
(47.6) 
0.587 
Pts with dyslipidemia 
(%) 
12 
(30.8) 
10 
(47.6) 
0.263 
Pts with Metabolic Syndrome 
(%) 
5 
(12.8) 
6 
(28.6) 
0.169 
Pts: patients. PSH: post-surgical hypcorticortisolism; PSH-: absence of PSH; PSH+: presence of PSH; 
MSC: midnight serum cortisol. UFC: urinary free cortisol; F-1mgDST: cortisol after 1 mg overnight 
dexamethasone suppression test. HC: hydrocortisone dose during substitutive therapy period. For 
plasma cortisol multiply x 27.56 to convert from μg/dL to nmol/L. For 24h urinary cortisol multiply x 
2.756 to convert from μg/24h to nmol/24h. For ACTH multiply x 0.22 to convert from pg/mL to 
pmol/L 
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Table 2. Pre-surgical clinical and biochemical features of patients with adrenal incidentalomas and 
with cortisol after 1 mg overnight dexamethasone suppression test below 1.2 µg/dL or ≥1.2 µg/dL 
 
F-1mgDST 
<1.2 µg/dL 
n=9 
F-1mgDST 
≥1.2 µg/dL 
n=51 
P value 
Females 
6 
(66.7) 
40 
(78.4) 
0.44 
Age                                            
(yrs)  
56.6±4.5 
48 – 63 
55.9±11.6 
24 – 75 
0.86 
BMI                                      
(kg/m
2
) 
26.6±2.9 
21.5 – 31.3 
28.4±6.0 
17.4 – 41.0 
0.38 
Duration of pre-surgical follow up 
(months) 
8.4±7.4 
1.0  24.0 
5.5±5.0 
0.5  19.6 
0.142 
HC doses (mg/day) 
20.0±0.0 
(20 – 20) 
21.1±2.5 
(20 – 30) 
0.21 
ACTH  
(pg/mL) 
10.1±6.0 
5.0 – 23.8 
9.3±5.2 
1.9 – 26.9 
0.69 
F-1mg-DST 
 (µg/dL) 
1.1±0.1 
0.9 – 1.1 
4.6±3.2 
1.2 – 13.7 
0.001 
UFC  
(µg/24hrs) 
36.6±17.7 
10.0 – 59.0 
66.8±43.2 
10.4 – 189.6 
0.04 
MSC 
(µg/dL) 
3.0±1.6 
1.0 – 5.5 
5.4±3.1 
1.2 – 12.5 
0.03 
Diameter of adenoma 
(cm) 
3.4±1.2 
1.5 – 5.7 
3.5±1.3 
1.2 – 9.0 
0.85 
Pts with type 2 diabetes mellitus 
(%) 
0 
(0.0) 
14 
(27.5) 
0.07 
Pts with arterial hypertension 
(%) 
3 
(33.3) 
30 
(58.8) 
0.15 
Pts with obesity 
(%) 
3 
(33.3) 
22 
(43.1) 
0.72 
Pts with dyslipidemia 
(%) 
0 
(0.0) 
22 
(43.1) 
0.02 
Pts with Metabolic Syndrome 
(%) 
0 
(0.0) 
11 
(21.6) 
0.19 
 
Pts: patients. MSC: midnight serum cortisol. UFC: urinary free cortisol; F-1mgDST: cortisol after 1 
mg overnight dexamethasone suppression test. For plasma cortisol multiply x 27.56 to convert from 
μg/dL to nmol/L. HC: hydrocortisone dose during substitutive therapy period . For 24h urinary 
cortisol multiply x 2.756 to convert from μg/24h to nmol/24h.  For ACTH multiply x 0.22 to convert 
from pg/mL to pmol/L 
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Figure 1 
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Figure 2 
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